| 國立成功大學 |
2024-07 |
Multicenter evaluation of the safety and efficacy of selective internal radiation therapy with yttrium-90 resin microspheres in Taiwan: data from the RESIN registry
|
Lee;Rheun-Chuan;Liang;Po-Chin;Liang;Huei-Lung;Chen;Yung-Fang;Yu;Chun-Yen;Cheng;Pin-Nan;Hung;Chien-Fu;Hsia;Cheng-Yuan;Lai;Hsueh-Chou;Ho;Ming-Chih;Cheng;Yu-Fan;Liu;Yi-Sheng;Chao;Yee;Chen;Chien-Hung |
| 國立成功大學 |
2024-06 |
Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Na�ve Patients from a Nationwide HCV Registry in Taiwan
|
Yang;Chun-Chi;Huang;Chung-Feng;Chang;Te-Sheng;Lo;Ching-Chu;Hung;Chao-Hung;Huang;Chien-Wei;Chong;Lee-Won;Cheng;Pin-Nan;Yeh;Ming-Lun;Peng;Cheng-Yuan;Cheng;Chien-Yu;Huang;Jee-Fu;Bair;Ming-Jong;Lin;Chih-Lang;Yang;Chi-Chieh;Wang;Szu-Jen;Hsieh;Tsai-Yuan;Lee;Tzong-Hsi;Lee;Pei-Lun;Wu;Wen-Chih;Lin;Chih-Lin;Su;Wei-Wen;Yang;Sheng-Shun;Wang;Chia-Chi;Hu;Jui-Ting;Mo;Lein-Ray;Chen;Chun-Ting;Huang;Yi-Hsiang;Chang;Chun-Chao;Huang;Chia-Sheng;Chen;Guei-Ying;Kao;Chien-Neng;Tai;Chi-Ming;Liu;Chun-Jen;Lee;Mei-Hsuan;Kuo;Hsing-Tao;Tsai;Pei-Chien;Dai;Chia-Yen;Kao;Jia-Horng;Lin;Han-Chieh;Chuang;Wang-Long;Tseng;Kuo-Chih;Chen;Chi-Yi;Yu;Ming-Lung |
| 國立成功大學 |
2024-06 |
Real-world effectiveness and safety of 8-week glecaprevir/pibrentasvir for treatment-naive patients from Taiwan nationwide HCV registry
|
Huang;Chung-Feng;Chang;Te-Sheng;Kuo;Hsing-Tao;Huang;Chien-Wei;Mo;Lien-Ray;Tai;Chi-Ming;Tseng;Kuo-Chih;Bair;Ming-Jong;Wang;Sih-Ren;Lo;Ching-Chu;Chong;Lee-Won;Cheng;Pin-Nan;Yeh;Ming-Lun;Peng;Cheng-Yuan;Cheng;Chien-Yu;Huang;Jee-Fu;Lin;Chih-Lang;Yang;Chi-Chieh;Hsieh;Tsai-Yuan;Lee;Tzong-Hsi;Lee;Pei-Lun;Wu;Wen-Chih;Lin;Chih-Lin;Su;Wei-Wen;Yang;Sheng-Shun;Wang;Chia-Chi;Hu;Jui-Ting;Chen;Chun-Ting;Huang;Yi-Hsiang;Chang;Chun-Chao;Huang;Chia-Sheng;Chen;Guei-Ying;Kao;Chien-Neng;Liu;Chun-Jen;Lee;Mei-Hsuan;Tsai;Pei-Chien;Dai;Chia-Yen;Kao;Jia-Horng;Lin;Han-Chieh;Chuang;Wan-Long;Hung;Chao-Hung;Chen;Chi-Yi;Yu;Ming-Lung |
| 國立成功大學 |
2024-06 |
Multinational randomized trial to investigate the efficacy of tenofovir alafenamide in reducing adverse clinical events in chronic hepatitis B patients who are beyond treatment indications by current guidelines (ATTENTION trial): first interim analysis
|
Lim;Young-Suk;Choi;Jonggi;Choi;Won-Mook;Kang;Wonseok;Kim;Gi-Ae;Kim;Joon, Hyung;Lee;Jeong-Hoon;Lee;Bin, Yun;Park;Hwa, Neung;Kwon;Young, So;Jang;Sun, Eun;Park;Young, Soo;Kim;Hoon, Ji;Yu;Ming-Lung;Chen;Chien-Hung;Hsu;(Holden), Yao-Chun;Bair;Ming-Jong;Cheng;Pin-Nan;Tung;Hung-Da;Chang;Te-Sheng;Chen;Chi-Yi;Lo;Chingchu;Tseng;Kuo-Chih;Yang;Sheng-Shun;Peng;Cheng-Yuan |
| 國立成功大學 |
2024-04 |
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan
|
Yu;Ming-Lung;Tai;Chi-Ming;Mo;Lein-Ray;Kuo;Hsing-Tao;Huang;Chung-Feng;Tseng;Kuo-Chih;Lo;Ching-Chu;Bair;Ming-Jong;Wang;Szu-Jen;Huang;Jee-Fu;Yeh;Ming-Lun;Chen;Chun-Ting;Tsai;Ming-Chang;Huang;Chien-Wei;Lee;Pei-Lun;Yang;Tzeng-Hue;Huang;Yi-Hsiang;Chong;Lee-Won;Chen;Chien-Lin;Yang;Chi-Chieh;Hung;Chao-Hung;Yang;Sheng-Shun;Cheng;Pin-Nan;Hsieh;Tsai-Yuan;Hu;Jui-Ting;Wu;Wen-Chih;Cheng;Chien-Yu;Chen;Guei-Ying;Zhou;Guo-Xiong;Tsai;Wei-Lun;Kao;Chien-Neng;Lin;Chih-Lang;Wang;Chia-Chi;Lin;Ta-Ya;Lin;Chih-Lin;Su;Wei-Wen;Lee;Tzong-Hsi;Chang;Te-Sheng;Liu;Chun-Jen;Dai;Chia-Yen;Chen;Chi-Yi;Kao;Jia-Horng;Lin;Han-Chieh;Chuang;Wan-Long;Peng;Cheng-Yuan |
| 國立成功大學 |
2024-01 |
Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B
|
Cheng;Pin-Nan;Feng;I-Cher;Chen;Jyh-Jou;Kuo;Hsing-Tao;Lee;Pei-Lun;Yu;Ming-Lung;Chiu;Yen-Cheng;Chiu;Hung-Chih;Chien;Shih-Chieh;Chen;Pei-Jer;Liu;Chun-Jen |
| 國立成功大學 |
2024-01 |
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction-associated fatty liver disease and cardiovascular diseases
|
Cheng;Pin-Nan;Chen;Wen-Jone;Hou;Charles, Jia-Yin;Lin;Chih-Lin;Chang;Ming-Ling;Wang;Chia-Chi;Chang;Wei-Ting;Wang;Chao-Yung;Lin;Chun-Yen;Hung;Chung-Lieh;Peng;Cheng-Yuan;Yu;Ming-Lung;Chao;Ting-Hsing;Huang;Jee-Fu;Huang;Yi-Hsiang;Chen;Chi-Yi;Chiang;Chern-En;Lin;Han-Chieh;Li;Yi-Heng;Lin;Tsung-Hsie;Kao;Jia-Horng;Wang;Tzung-Dau;Liu;Ping-Yen;Wu;Yen-Wen;Liu;Chun-Jen |
| 國立成功大學 |
2024-01 |
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program
|
Lu;Ming-Ying;Huang;Chung-Feng;Hung;Chao-Hung;Tai;Chi-Ming;Mo;Lein-Ray;Kuo;Hsing-Tao;Tseng;Kuo-Chih;Lo;Ching-Chu;Bair;Ming-Jong;Wang;Szu-Jen;Huang;Jee-Fu;Yeh;Ming-Lun;Chen;Chun-Ting;Tsai;Ming-Chang;Huang;Chien-Wei;Lee;Pei-Lun;Yang;Tzeng-Hue;Huang;Yi-Hsiang;Chong;Lee-Won;Chen;Chien-Lin;Yang;Chi-Chieh;Yang;Sheng-Shun;Cheng;Pin-Nan;Hsieh;Tsai-Yuan;Hu;Jui-Ting;Wu;Wen-Chih;Cheng;-Yu, Chien;Chen;Guei-Ying;Zhou;Guo-Xiong;Tsai;Wei-Lun;Kao;Chien-Neng;Lin;Chih-Lang;Wang;-Chi, Chia;Lin;Ta-Ya;Lin;Chih-Lin;Su;-Wen, Wei;Lee;Tzong-Hsi;Chang;Te-Sheng;Liu;Chun-Jen;Dai;-Yen, Chia;Kao;Jia-Horng;Lin;Han-Chie;Chuang;-Long, Wan;Peng;Cheng-Yuan;Tsai;Chun-Wei;Chen;Chi-Yi;Yu;Ming-Lung |
| 國立成功大學 |
2023-10 |
Chronic Hepatitis C Virus Infection: An Ongoing Challenge in Screening and Treatment
|
Tsai;Wei-Chu;Chiang;Hseuh-Chien;Chiu;Yen-Cheng;Chien;Shih-Chieh;Cheng;Pin-Nan;Chiu;Hung-Chih |
| 國立成功大學 |
2023-03 |
Reversibility of some oxidative stress markers in chronic hepatitis C patients after receiving direct-acting antiviral agents
|
Cheng;Pin-Nan;Sun;Hung-Yu;Feng;I-Che;Wang;Sin-Tian;Chiu;-Cheng, Yen;Chiu;Hung-Chih;Chien;Shih-Chieh;Young;Kung-Chia |
| 國立成功大學 |
2023-02 |
Interdependence of glycemic and lipid modulation in cured chronic hepatitis C patients by direct-acting antiviral agents
|
Cheng;Pin-Nan;Sun;Hung-Yu;Feng;I-Che;Chiu;Yen-Cheng;Wang;Sin-Tian;Tan;Charmaine, Dyoness;Chiu;Hung-Chih;Chien;Shih-Chih;Young;Kung-Chia |
| 國立成功大學 |
2022-12 |
Entecavir Prevents HBV Reactivation During Direct Acting Antivirals for HCV/HBV Dual Infection: A Randomized Trial
|
Cheng;Pin-Nan;Liu;Chun-Jen;Chen;Chi-Yi;Tseng;Kuo-Chih;Lo;Ching-Chu;Peng;Cheng-Yuan;Lin;Chih-Lin;Chiu;Hung-Chih;Chiu;Yen-Cheng;Chen;Pei-Jer |
| 國立成功大學 |
2022-11 |
Higher Risk of Tumor Recurrence in NASH-Related Hepatocellular Carcinoma Following Curative Resection
|
Chien;Shih-Chieh;Lin;Yih-Jyh;Lee;Chun-Te;Chiu;Yen-Cheng;Chou;Tsung-Ching;Chiu;Hung-Chih;Tsai;Hung-Wen;Su;Che-Min;Yang;Tsung-Han;Chiang;Hsueh-Chien;Tsai;Wei-Chu;Yang;Kai-Chun;Cheng;Pin-Nan |
| 國立成功大學 |
2022-11 |
Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/ pibrentasvir for genotype 6 chronic hepatitis C
|
Chen;Jyh-Jou;Chiu;Yen-Cheng;Lee;Pei-Lun;Tung;Hung-Da;Chiu;Hung-Chih;Chien;Shih-Chieh;Cheng;Pin-Nan |
| 國立成功大學 |
2022-05 |
Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral
|
Huang;Shang-Chin;Cheng;Pin-Nan;Liu;Chen-Hua;Yang;Hung-Chih;Su;Tung-Hung;Tseng;Tai-Chung;Chen;Pei-Jer;Kao;Jia-Horng;Liu;Chun-Jen |
| 國立成功大學 |
2021-07 |
Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis
|
Tsai;Hong-Ming;Han;Meng-Zhi;Lin;Yih-Jyh;Chang;Ting-Tsung;Chen;Chiung-Yu;Cheng;Pin-Nan;Chuang;Chiao-Hsiung;Wu;I-Chin;Chen;Po-Jun;Kang;Jui-Wen;Chiu;Yen-Cheng;Chiu;Hung-Chih;Chien;Shih-Chieh;Kuo;Hsin-Yu |
| 國立成功大學 |
2021-06 |
Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg Loss
|
Wu;I-Chin;Liu;Wen-Chun;Chiu;Yen-Cheng;Chiu;Hung-Chih;Cheng;Pin-Nan;Chang;Ting-Tsung |
| 國立成功大學 |
2021-03 |
Effectiveness and safety of ledipasvir/ sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan
|
Chiu;Hung-Chih;Chiu;Yen-Cheng;Yang;Er-Hsiang;Chang;Ting-Tsung;Chien;Shih-Chieh;Wu;I-Chin;Wu;Chun-Hsien;Cheng;Pin-Nan |
| 國立成功大學 |
2021-01 |
Persistent augmentation of central arterial stiffness following viral clearance by direct-acting antivirals in chronic hepatitis C
|
Chen;Ju-Yi;Cheng;Pin-Nan;Chiu;Yen-Cheng;Chiu;Hung-Chih;Tsai;Wei-Chuan;Tsai;Liang-Miin |
| 國立成功大學 |
2020-07 |
Assessment of Serological Early Biomarker Candidates for Lung Adenocarcinoma by using Multiple Reaction Monitoring-Mass Spectrometry
|
Wu;Hsin-Yi;Pan;Yu-Yi;Kopylov;Arthur, T.;Zgoda;Victor;Ma;Mi-Chia;Wang;Ching-Hsun;Su;Wu-Chou;Lai;Wu-Wei;Cheng;Pin-Nan;Liao;Pao-Chi |
| 國立成功大學 |
2020-05 |
Limited drug-drug interaction of elbasvir/grazoprevir for chronic hepatitis C
|
Liu;Chun-Jen;Tseng;Kuo-Chih;Lo;Ching-Chu;Tseng;I-Hao;Cheng;Pin-Nan |
| 國立成功大學 |
2020-04 |
Genotyping of immune-related loci associated with delayed HBeAg seroconversion in immune-active chronic hepatitis B patients
|
Liu;Wen-Chun;Wu;I-Chin;Chiu;Yen-Cheng;Tseng;Kuo-Chih;Chen;Chi-Yi;Chiu;Hung-Chih;Cheng;Pin-Nan;Chang;Ting-Tsung |
| 國立成功大學 |
2020-03 |
Real-world effectiveness and safety of ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan
|
Chen;Jyh-Jou;Lee;Pei-Lun;Chiu;Hung-Chih;Tung;Hung-Da;Chiu;Yen-Cheng;Cheng;Pin-Nan |
| 國立成功大學 |
2019-11 |
Insulin Resistance Associated Disorders Pivoting Long-Term Hepatitis B Surface Antigen Decline During Entecavir Therapy
|
Lin;Tien-Ching;Liu;Wen-Chun;Hsu;Yu-Hsiang;Lin;Jia-Jhen;Chiu;Yen-Cheng;Chiu;Hung-Chih;Cheng;Pin-Nan;Chen;Chiung-Yu;Chang;Ting-Tsung;Wu;I-Chin |
| 國立成功大學 |
2019-05 |
Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan
|
Cheng;Pin-Nan;Chiu;Yen-Cheng;Chien;Shih-Chieh;Chiu;Hung-Chih |
